Novo Nordisk A/S (NYSE:NVO – Get Free Report) was upgraded by equities researchers at UBS Group from a “sell” rating to a ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Alzheimer’s drugs could unlock a $13 billion market by 2030, with Biogen, Eli Lilly, Novo Nordisk, Roche, and UCB leading the ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

El Lilly’s blockbuster weight-loss drug Zepbound is now eligible for coverage under Medicare prescription drug plans, when ...

High unmet medical need for therapies that can reduce the substantial treatment burden affecting millions of patients globallyCombined in-licensing and financing for a novel long-acting clinical ...

MoneyShow presents top investment ideas for 2024 from leading advisors. Part 2 includes Neo Performance Metals, Fannie Mae, ...

Yields on European government bonds remained elevated, with the German 10-year bund yield hitting its highest level in six ...

Since the election, Trump has proposed tariffs on Canada-made goods, including cars, while also boasting about making Canada ...

Topline data were announced from a phase 3 trial evaluating CagriSema in overweight or obese patients without type 2 diabetes.

While campaigning for Donald Trump in October, Elon Musk claimed he could slash “at least $2 trillion” in government spending ...